Search alternatives:
host resistance » plant resistance (Expand Search)
weak resistance » wear resistance (Expand Search), heat resistance (Expand Search), crack resistance (Expand Search)
decrease tumor » increased tumor (Expand Search)
release host » release heat (Expand Search), release soil (Expand Search)
Showing 141 - 160 results of 1,959 for search '(( release host resistance ) OR ((( decrease tumor resistance ) OR ( decrease weak resistance ))))', query time: 0.69s Refine Results
  1. 141
    Sanger sequencing of the Mp3g19030.1 gene in Mp<i>thar</i> mutants and amino acid alignment of RTN4IP1 homologues.

    Sanger sequencing of the Mp3g19030.1 gene in Mp<i>thar</i> mutants and amino acid alignment of RTN4IP1 homologues. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  2. 142
    Mp<i>rtn4ip1l</i> mutants are defective in thaxtomin A metabolism.

    Mp<i>rtn4ip1l</i> mutants are defective in thaxtomin A metabolism. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 143
    Species included in the phylogenetic analysis of <i>RTN4IP1</i> homologues.

    Species included in the phylogenetic analysis of <i>RTN4IP1</i> homologues. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 144
    Dose-response curve of UV-B radiation on <i>M</i>. <i>polymorpha</i> spores.

    Dose-response curve of UV-B radiation on <i>M</i>. <i>polymorpha</i> spores. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 145
    Amino acid alignments of PAM16 homologues and mutations identified in Mp<i>pam16</i> mutants.

    Amino acid alignments of PAM16 homologues and mutations identified in Mp<i>pam16</i> mutants. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 146
    Sanger sequencing of Mp<i>ahas</i><sup><i>chlr</i></sup> mutants.

    Sanger sequencing of Mp<i>ahas</i><sup><i>chlr</i></sup> mutants. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 147
    Numerical data underlying graphs and summary statistics.

    Numerical data underlying graphs and summary statistics. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 148
    The Mp<i>RTN4IP1L</i> (Mp3g19030.1) gene is mutated in 3 Mp<i>thar</i> mutants.

    The Mp<i>RTN4IP1L</i> (Mp3g19030.1) gene is mutated in 3 Mp<i>thar</i> mutants. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 149
    A mechanism of non-target site resistance conferred by loss-of-function of <i>PAM16</i> is conserved in <i>M</i>. <i>polymorpha</i>.

    A mechanism of non-target site resistance conferred by loss-of-function of <i>PAM16</i> is conserved in <i>M</i>. <i>polymorpha</i>. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 150
    Nucleotide and amino acid alignments of the Mp<i>RTN4IP1L</i> genes and MpRTN4IP1L proteins of Mp<i>rtn4ip1l</i> mutants.

    Nucleotide and amino acid alignments of the Mp<i>RTN4IP1L</i> genes and MpRTN4IP1L proteins of Mp<i>rtn4ip1l</i> mutants. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 151
    LC-MS/MS analysis of thaxtomin A and its putative metabolite in wild type and Mp<i>rtn4ip1l</i> mutant extracts.

    LC-MS/MS analysis of thaxtomin A and its putative metabolite in wild type and Mp<i>rtn4ip1l</i> mutant extracts. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 152
    Amino acid sequences and tree files used to build phylogenetic trees for PAM16 and RTN4IP1 homologues.

    Amino acid sequences and tree files used to build phylogenetic trees for PAM16 and RTN4IP1 homologues. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 153
    Mp<i>rtn4ip1l</i> mutants are defective in coenzyme Q synthesis and overproduce reactive oxygen species.

    Mp<i>rtn4ip1l</i> mutants are defective in coenzyme Q synthesis and overproduce reactive oxygen species. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 154
    Homologues of the <i>A</i>. <i>thaliana</i> gene AT3G59280 identified by BlastP search (E value < 1E-5).

    Homologues of the <i>A</i>. <i>thaliana</i> gene AT3G59280 identified by BlastP search (E value < 1E-5). by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 155
    Components of ½ Gamborg medium.

    Components of ½ Gamborg medium. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 156
    Primer list.

    Primer list. by Chloe Casey (14341756)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 157
    Image_1_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif

    Image_1_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…Changes in circulating tumor cells after treatment were consistent with serum level CA125 in the patient with stable disease (both decreased), while differences were observed in the two patients with disease progression (increased CA125 in both and decreased CTC in the patient with better immune response), suggesting that variation of circulating tumor cells was more consistent with immune response and reflected efficacy directly. …”
    Save to List
    Saved in:
  18. 158
    Image_3_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif

    Image_3_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…Changes in circulating tumor cells after treatment were consistent with serum level CA125 in the patient with stable disease (both decreased), while differences were observed in the two patients with disease progression (increased CA125 in both and decreased CTC in the patient with better immune response), suggesting that variation of circulating tumor cells was more consistent with immune response and reflected efficacy directly. …”
    Save to List
    Saved in:
  19. 159
    Image_4_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif

    Image_4_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…Changes in circulating tumor cells after treatment were consistent with serum level CA125 in the patient with stable disease (both decreased), while differences were observed in the two patients with disease progression (increased CA125 in both and decreased CTC in the patient with better immune response), suggesting that variation of circulating tumor cells was more consistent with immune response and reflected efficacy directly. …”
    Save to List
    Saved in:
  20. 160
    Image_2_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif

    Image_2_Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.tif by Hongyan Cheng (445898)

    Published 2021
    “…Changes in circulating tumor cells after treatment were consistent with serum level CA125 in the patient with stable disease (both decreased), while differences were observed in the two patients with disease progression (increased CA125 in both and decreased CTC in the patient with better immune response), suggesting that variation of circulating tumor cells was more consistent with immune response and reflected efficacy directly. …”
    Save to List
    Saved in:

Search Tools: